4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
9.46
+0.01 (0.11%)
At close: Apr 28, 2026, 4:00 PM EDT
9.42
-0.04 (-0.42%)
After-hours: Apr 28, 2026, 4:10 PM EDT
4D Molecular Therapeutics Employees
4D Molecular Therapeutics had 196 employees as of December 31, 2025. The number of employees decreased by 31 or -13.66% compared to the previous year.
Employees
196
Change (1Y)
-31
Growth (1Y)
-13.66%
Revenue / Employee
$434,740
Profits / Employee
-$714,842
Market Cap
482.95M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 674 |
| Ginkgo Bioworks Holdings | 485 |
| ADC Therapeutics | 193 |
| Entrada Therapeutics | 152 |
| Aura Biosciences | 113 |
| Prelude Therapeutics | 79 |
| Upstream Bio | 75 |
| Larimar Therapeutics | 71 |
FDMT News
- 11 days ago - 4DMT Announces New Employment Inducement Grants - GlobeNewsWire
- 5 weeks ago - 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewsWire
- 6 weeks ago - 4DMT to Participate in Upcoming Investor Meetings - GlobeNewsWire
- 6 weeks ago - 4D Molecular Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts
- 7 weeks ago - 4D Molecular Therapeutics Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 2 months ago - 4D Molecular Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - 4DMT to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - 4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD - GlobeNewsWire